Aim immunotech bolsters intellectual property portfolio for ampligen® with issuance of new netherlands utility patent covering ampligen® and other aim developed dsrna products for use in covid-19 treatment or prevention

Further expansion of patent portfolio supports of the company's extensive ampligen research program across multiple types of cancers and viral diseases, including covid-19 in the netherlands further expansion of patent portfolio supports of the company's extensive ampligen research program across multiple types of cancers and viral diseases, including covid-19 in the netherlands
AIM Ratings Summary
AIM Quant Ranking